Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Outlook Therapeutics nets $26.8mm via FOPO

Executive Summary

Ophthalmic-focused Outlook Therapeutics Inc. (formerly Oncobiologics) netted $26.8mm through a follow-on offering of 10.34mm common shares at $2.75. The company also issued 15-month warrants to purchase up to 10.34mm common shares and five-year warrants to buy another 10.34mm shares; the warrants are exercisable at $2.90 per share. Outlook will use the proceeds for Phase III development of ONS5010 for wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Additional funds will help repay $5mm in outstanding principal and accrued interest on its 5% senior secured notes due June 2019.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies